Your shopping cart is currently empty

EHNA hydrochloride is a selective inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2) and adenosine deaminase (ADA) with anticancer activity, increasing intracellular adenosine concentration in a treatment time-dependent manner. EHNA hydrochloride inhibits PHA and NaI04 mitogenesis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $99 | - | In Stock |
| Description | EHNA hydrochloride is a selective inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2) and adenosine deaminase (ADA) with anticancer activity, increasing intracellular adenosine concentration in a treatment time-dependent manner. EHNA hydrochloride inhibits PHA and NaI04 mitogenesis. |
| Targets&IC50 | PDE2A (human):0.8 μM |
| In vitro | EHNA hydrochloride exhibits normal Michaelian kinetics of inhibition for the cyclic GMP-stimulated PDE2 activity with Hill plots near unity. EHNA hydrochloride prevents dAdo degradation and increases mitochondrial dATP levels in fibroblasts. EHNA hydrochloride completely ablates the ability of cyclic GMP to activate PDE2 activity, whilst having a much smaller inhibitory effect on the unstimulated PDE2 activity. [2] |
| Molecular Weight | 313.83 |
| Formula | C14H24ClN5O |
| Cas No. | 58337-38-5 |
| Smiles | [C@H](CCCCCC)([C@@H](C)O)N1C=2C(N=C1)=C(N)N=CN2.Cl |
| Relative Density. | 1.31g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (254.92 mM), Sonication is recommended. DMSO: 60 mg/mL (191.19 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.